Craif presents study results of urinary biomarker for SLE at ACR Convergenc

Craif (Location: Bunkyo-ku, Tokyo, CEO: Ryuichi Onose, hereinafter referred to as “Craif”) presented the results of a study on systemic lupus erythematosus (SLE) at the ACR Convergence 2021, which was held online from 1st to 10th November. With the results of this research, Craif aims to commercialize liquid biopsy for order-made medicine of SLE using urinary miRNA.

■Outline of this study
We have conducted the study using our distinctive microfluidic nanowire device to analyze the urinary miRNA in SLE patients. In this presentation, we reported that (1) we identified many SLE-related biomarker candidates through urinary miRNA analysis, (2) we identified biomarkers associated with the severity of SLE, and (3) combining with machine learning techniques, we succeeded to distinguish SLE patients and healthy individuals with high accuracy based on miRNA expression patterns.

■ Outline of ACR Convergence 2021
ACR Convergence is the annual meeting of the American College of Rheumatology, a forum for collaboration, gathering, and learning about rheumatology. It combines basic science, clinical science, business education, and interactive discussions to improve patient care.
This year’s ACR Convergence 2021 will cover more than 2,000 abstracts and expert presentations by more than 320 clinicians, researchers, and healthcare professionals.

Dates: 1st to 10th November 2021
Venue: Online
Official website: